Clik here to view.
Humansa仁山优社委任苏嘉威先生为行政总裁推出医疗健康全新模式 带领品牌于香港及内地发展
香港 (美国商业资讯)– 新世界集团旗下的医疗健康业务Humansa仁山优社今天宣布委任苏嘉威（Don So）先生为行政总裁，由即日起生效。苏先生现为新世界发展新兴业务负责人，借助曾在全球顶尖企任职业务发展策略及执行的成功经验，他将会推动Humansa仁山优社在香港及内地市场的扩展布局。在他的领导下，Humansa仁山优社将在粤港澳大湾区提供高质量、以客户为中心的全面专业医疗及健康服务。...
View ArticleClik here to view.
Róbert Wessman Inaugurates New London Offices of His Private Equity Fund Aztiq
REYKJAVIK, Iceland Róbert Wessman, the founder and principal shareholder in the Alvo group of leading pharmaceutical companies, formally opened the new London offices of his investment fund, Aztiq,...
View ArticleClik here to view.
蓝洞新消费发布关于《世卫组织烟草控制框架公约》缔约方会议第九届会议召开前全球倡导烟草减害的专题报道
中国深圳 中国领先的电子烟媒体蓝洞新消费(Bluehole New Consumption)今天发表了一篇专题报道，介绍了《世界卫生组织烟草控制框架公约》缔约方会议第九届会议(WHO FCTC COP9)召开前全球各界倡导烟草减害的情况，同时指出雾化技术在医疗保健等领域具有广阔的前景。...
View ArticleClik here to view.
Regencell Bioscience Holdings Limited Included in the MSCI World Micro Cap Index
HONG KONG Regencell Bioscience Holdings Limited (NASDAQ: RGC) (“Regencell” or the “Company”), an early-stage bioscience company focuses on the research, development and commercialization of TCM for...
View ArticleClik here to view.
PeptiGrowth Inc. Is Launching A Novel Synthetic Peptide TGFβ1 Inhibitor,...
TOKYO PeptiGrowth Inc. (Headquarters: Chiyoda-ku, Tokyo, President: Jiro Sugimoto) has successfully developed a novel peptide called TGFβ1 inhibitor (TGFβ1 binding peptide) which binds to TGFβ1 to...
View ArticleClik here to view.
Applied BioCode Launches 28 New Fungal Analyte Specific Reagents in the US
SANTA FE SPRINGS, Calif. Applied BioCode announced today that it has released 28 Fungal Analyte Specific Reagents (ASRs) for use in molecular tests. (15 ASRs for mold pathogens, 10 ASRs for yeast...
View ArticleClik here to view.
ブルーホールが、WHO FCTC COP9に先立ち、たばこの有害性低減への世界的な支持に関する特集記事を掲載
中国・深セン （ビジネスワイヤ） — 中国の大手電子たばこメディアであるブルーホール・ニュー・コンサンプションは本日、WHO FCTC COP9に先立ち、たばこの有害性低減への世界的な支持に加え、医療やその他の分野で有望な霧化に関する特集記事を掲載しました。 以下は、英語記事の全文です。...
View ArticleClik here to view.
BeiGene Launches Proposed Initial Public Offering on the STAR Market in China
CAMBRIDGE, Mass. & BEIJING BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160), a global, science-driven biotechnology company focused on developing innovative and affordable medicines to improve...
View ArticleClik here to view.
Apollomics Inc. Doses First Patient in Phase 3 Clinical Trial in China of...
ROCKVILLE, Md. GlycoMimetics, Inc. (Nasdaq: GLYC) announced today that Apollomics has dosed the first patient in China in a Phase 3 clinical trial of APL-106 (uproleselan injection) for the...
View ArticleClik here to view.
BeiGene Announces Approval of BRUKINSA (zanubrutinib) in the European Union...
BASEL, Switzerland & CAMBRIDGE, Mass. & BEIJING BeiGene (NASDAQ: BGNE; HKEX: 06160) announced today that the European Commission (EC) approved BRUKINSA® (zanubrutinib) for the treatment of...
View ArticleClik here to view.
Takeda’s LIVTENCITYTM (maribavir) Approved by U.S. FDA as the First and Only...
OSAKA, Japan & CAMBRIDGE, Mass. Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) today announced that the U.S. Food and Drug Administration (FDA) has approved LIVTENCITY™...
View ArticleClik here to view.
Canon Medical Reinforces Commitment to AI Innovation With New Altivity Brand
OTAWARA, Japan Canon Medical has today announced the launch of Altivity, a new AI innovation brand, that consolidates machine learning and deep learning technologies to deliver uncompromised quality...
View ArticleClik here to view.
Cultural Corps of Korean Buddhism Holds Digital Programs to Promote...
SEOUL, South Korea The Cultural Corps of Korean Buddhism (Director Ven.Won-Kyung) announced that it runs ‘Sustainable Korean Temple Food 2021,’ an online event designed to introduce the sustainable...
View ArticleClik here to view.
MTTIとモンロールが無担体Lu-177の臨床供給契約を締結
米ペンシルベニア州ウェストチェスター & イスタンブール エジザージュバシュ・モンロール・ニュークリア・プロダクツ（以下、モンロール）は本日、臨床段階にあるバイオテクノロジー企業として革新的な希少がん向け治療薬の開発に傾注しているモレキュラー・ターゲティング・テクノロジーズ(MTTI）との間で、医療用放射性同位元素である無担体177Luの供給契約を締結したと発表しました。...
View ArticleClik here to view.
MTTI和Monrol已签署镥-177 n.c.a.临床供应协议
宾夕法尼亚州西切斯特和伊斯坦布尔 –(美国商业资讯)–Eczacıbaşı-Monrol Nuclear Products Co. (Monrol)今天宣布与专注于开发用于罕见癌症之创新疗法的临床阶段生物技术公司Molecular Targeting Technologies, Inc. (MTTI)达成医用放射性同位素无载体177镥（n.c.a.177镥）的供应协议。...
View ArticleClik here to view.
Canon Medical Signals Its Support for a Multicenter Ultrasound Liver...
OTAWARA, Tochigi Prefecture, Japan Canon Medical announced today its support for the iLEAD (innovative Liver, Elasticity, Attenuation and Dispersion) study, an international multicenter study aiming...
View ArticleClik here to view.
European Commission Approves KEYTRUDA® (pembrolizumab) Plus LENVIMA®...
KENILWORTH, N.J. & TOKYO Merck (NYSE: MRK), known as MSD outside the United States and Canada, and Eisai today announced that the European Commission has approved the combination of KEYTRUDA,...
View ArticleClik here to view.
武田在美国血液学会(ASH)第63届年会上发布可促进血液病和肿瘤患者治疗的新研究成果
马萨诸塞州剑桥和日本大阪 武田药品工业株式会社(Takeda Pharmaceutical Company Limited,...
View ArticleClik here to view.
武田薬品が第63回米国血液学会（ASH）年次総会で血液疾患およびオンコロジーの領域における患者治療を前進させる新たな研究を発表
米マサチューセッツ州ケンブリッジ & 大阪...
View ArticleClik here to view.
GenBody America’s COVID-19 Antigen Tests Now Authorized for Serial Testing...
JURUPA VALLEY, California GenBody America is proud to announce that its COVID-19 antigen test kits are now authorized for use for individuals without symptoms or other epidemiological reasons to...
View Article